Regencell Bioscience Lim...

NASDAQ: RGC · Real-Time Price · USD
12.70
-0.72 (-5.37%)
At close: Aug 14, 2025, 3:59 PM
12.69
-0.08%
Pre-market: Aug 15, 2025, 06:31 AM EDT

Regencell Bioscience Income Statement

Financials in USD. Fiscal year is July - June.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Jun 30, 2024 Jun 30, 2023 Jun 30, 2022 Jun 30, 2021
Revenue
n/a n/a n/a n/a
Cost of Revenue
745.59K 769.69K 604.4K 26.46K
Gross Profit
-745.59K -769.69K -604.4K -26.46K
Operating Income
-4.74M -6.27M -7.62M -1.38M
Interest Income
n/a n/a n/a n/a
Pretax Income
-4.36M -6.06M -7.59M -1.35M
Net Income
-4.3M -5.87M -7.42M -1.35M
Selling & General & Admin
2.92M 4.69M 5.11M 943.04K
Research & Development
1.07M 1.58M 2.51M 438.32K
Other Expenses
n/a 211.34K 23.21K 34.62K
Operating Expenses
3.99M 6.27M 7.62M 1.38M
Interest Expense
n/a n/a n/a n/a
Selling & Marketing Expenses
125.43K 262.66K 25.27K 1.58K
Cost & Expenses
4.74M 6.27M 7.62M 1.38M
Income Tax Expense
n/a n/a n/a n/a
Shares Outstanding (Basic)
494.49M 494.49M 494.49M 480.4M
Shares Outstanding (Diluted)
494.49M 494.49M 494.49M 480.4M
EPS (Basic)
-0.01 -0.01 -0.01 -0.00
EPS (Diluted)
-0.01 -0.01 -0.01 -0.00
EBITDA
-3.62M -5.29M -6.99M -1.35M
EBIT
-4.36M -6.27M -7.62M -1.38M
Depreciation & Amortization
745.59K 769.69K 604.4K 26.46K